Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

THTX

Theratechnologies Inc

Dec 12 • 04:00PM ET

1.42

Dollar change -0.03
Percentage change -2.07	%

Healthcare • Biotechnology • Canada • NASD

Peers: REGN VRTX BIIB BMRN SRPT NBIX RARE PBYI ARDX ENTA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.09	Insider Own	21.08%	Shs Outstand	45.98M	Perf Week	-5.33%
Market Cap	34.36M	Forward P/E	11.14	EPS next Y	0.13	Insider Trans	0.00%	Shs Float	19.10M	Perf Month	12.08%
Income	-3.16M	PEG	-	EPS next Q	0.05	Inst Own	60.26%	Short Float	0.18%	Perf Quarter	5.19%
Sales	84.32M	P/S	0.41	EPS this Y	103.85%	Inst Trans	1.33%	Short Ratio	0.68	Perf Half Y	12.70%
Book/sh	-0.43	P/B	-	EPS next Y	264.29%	ROA	-5.00%	Short Interest	0.03M	Perf Year	-8.39%
Cash/sh	1.61	P/C	0.88	EPS next 5Y	-	ROE	-	52W Range	1.08 - 2.58	Perf YTD	-12.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-29.97%	ROI	-18.80%	52W High	-44.96%	Beta	1.42
Dividend TTM	-	Quick Ratio	0.97	Sales past 5Y	6.75%	Gross Margin	74.82%	52W Low	31.48%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	1.08	EPS Y/Y TTM	92.12%	Oper. Margin	13.72%	RSI (14)	57.07	Volatility	8.36% 6.19%
Employees	114	Debt/Eq	-	Sales Y/Y TTM	5.75%	Profit Margin	-3.75%	Recom	1.50	Target Price	4.73
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	303.25%	Payout	-	Rel Volume	0.70	Prev Close	1.45
Sales Surprise	-5.76%	EPS Surprise	100.00%	Sales Q/Q	8.37%	Earnings	Oct 10 BMO	Avg Volume	49.88K	Price	1.42
SMA20	9.13%	SMA50	11.36%	SMA200	7.51%	Trades		Volume	35,145	Change	-2.07%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-17-22	Initiated	Cantor Fitzgerald	Overweight	$9
Jul-29-21	Downgrade	Canaccord Genuity	Buy → Hold	$8 → $3

Dec-10-24 03:15PM	Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA (GlobeNewswire) -9.68%
Dec-09-24 07:30AM	Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer (GlobeNewswire) +9.15%
Dec-05-24 07:35AM	Theratechnologies enters exclusive licensing agreement with Ionis (TipRanks) +5.63%
06:59AM	Theratechnologies to license Ionis' RNA-targeted therapies in Canada (Pharmaceutical Business Review)
Dec-04-24 07:30AM	Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada (GlobeNewswire) +7.17%
04:30PM	Loading…
Dec-03-24 04:30PM	Theratechnologies Announces Resumed Production of EGRIFTA SV (GlobeNewswire)
07:47AM	Theratechnologies secures up to $75M in new credit facilities (TipRanks)
Dec-02-24 07:30AM	Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Quebec (GlobeNewswire) +6.61%
07:30AM	Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Qu bec (GlobeNewswire)
Nov-26-24 07:30AM	Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review (GlobeNewswire)
Oct-17-24 02:00PM	Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV (GlobeNewswire)
07:30AM	Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance (GlobeNewswire)
Oct-11-24 03:01AM	Theratechnologies Inc (THTX) Q3 2024 Earnings Call Highlights: Strong Profitability Amid ... (GuruFocus.com)
Oct-10-24 07:45AM	Theratechnologies: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024 (GlobeNewswire)
09:02AM	Loading…
Oct-09-24 09:02AM	Earnings to Watch: Theratechnologies Inc (TSX:TH) Reports Q3 2024 Result (GuruFocus.com)
07:30AM	Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV (GlobeNewswire)
Sep-26-24 07:30AM	Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire)
Sep-19-24 12:38PM	Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays (Benzinga)
Sep-17-24 05:00PM	Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV in Early 2025 (GlobeNewswire) -12.41%
Sep-09-24 07:30AM	Theratechnologies to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-01-24 08:50AM	Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value Investors (Zacks)
Jul-16-24 08:50AM	Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain Stock (Zacks)
Jul-10-24 12:52PM	THTX Stock Earnings: Theratechnologies Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
09:20AM	HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars (Benzinga)
08:57AM	Theratechnologies: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024 (GlobeNewswire)
Jun-26-24 07:30AM	Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire) +19.23%
Jun-05-24 08:50AM	Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-23-24 05:00PM	Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors (GlobeNewswire)
04:30PM	Loading…
May-09-24 04:30PM	Theratechnologies Reports on its Annual Meeting of Shareholders (GlobeNewswire)
May-02-24 07:30AM	Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting (GlobeNewswire)
Apr-23-24 12:00PM	Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-15-24 04:15PM	Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders (GlobeNewswire) -8.45%
Apr-11-24 07:30AM	Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-10-24 11:52AM	THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:21AM	Theratechnologies: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 (GlobeNewswire)
Apr-08-24 04:30PM	Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology Oncology Platform (GlobeNewswire) +6.21%
Apr-05-24 11:00AM	Theratechnologies Appoints Elina Tea to its Board of Directors (GlobeNewswire)
Apr-03-24 07:30AM	Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire)
Mar-28-24 07:30AM	Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform (GlobeNewswire) +13.70%
Mar-22-24 09:36AM	Theratechnologies Announces Update on its Preclinical Oncology Research Program (GlobeNewswire)
Mar-21-24 08:00PM	Theratechnologies Appoints Jordan Zwick to its Board of Directors (GlobeNewswire)
07:30AM	Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer (GlobeNewswire)
Feb-29-24 04:34PM	Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau (GlobeNewswire)
Feb-27-24 07:30AM	Theratechnologies Receives Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from FDA (GlobeNewswire)
Feb-26-24 08:50AM	Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Feb-21-24 08:45AM	Theratechnologies: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance (GlobeNewswire)
Feb-20-24 07:30AM	Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action (GlobeNewswire)
Feb-15-24 07:30AM	Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer (GlobeNewswire)
Feb-06-24 07:30AM	Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update (GlobeNewswire) +5.10%
Jan-24-24 07:00AM	Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA (GlobeNewswire) -13.95%
Jan-23-24 07:30AM	Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application (GlobeNewswire) -7.03%
Jan-02-24 07:30AM	Theratechnologies Submits sBLA for Trogarzo Intramuscular (IM) Method of Administration to FDA (GlobeNewswire)
Dec-21-23 04:09PM	Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement (PR Newswire) +5.30%
Dec-19-23 05:08AM	3 Biotech Stock Buys to Boost and Supercharge Portfolios (Entrepreneur: Stocks)
Dec-13-23 07:30AM	Theratechnologies Announces FDA Approval of Trogarzo 90-Second Intravenous (IV) Push Loading Dose (GlobeNewswire)
Nov-24-23 07:30AM	Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award (GlobeNewswire) +13.33%
Oct-31-23 12:34PM	Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement (GlobeNewswire)
Oct-26-23 09:11AM	Why Is Theratechnologies (THTX) Stock Down 22% Today? (InvestorPlace) -28.05%
08:00AM	Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement (GlobeNewswire)
Oct-25-23 04:13PM	Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement (GlobeNewswire)
Oct-24-23 07:00AM	Theratechnologies Announces Operational Update (GlobeNewswire) -10.95%
Oct-19-23 07:30AM	Theratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV (GlobeNewswire)
Oct-16-23 07:30AM	Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon (GlobeNewswire)
Oct-13-23 07:30AM	Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs) (GlobeNewswire)
07:00AM	Theratechnologies Announces Results from Trogarzo (Ibalizumab-uiyk) Intramuscular Administration Study (GlobeNewswire)
Oct-12-23 07:30AM	Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer (GlobeNewswire)
Oct-04-23 07:30AM	Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA (GlobeNewswire)
Sep-26-23 07:47AM	Theratechnologies: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -16.19%
07:30AM	Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates (GlobeNewswire)
Sep-25-23 07:30AM	Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility (GlobeNewswire)
07:00AM	Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review (GlobeNewswire)
Sep-20-23 07:00AM	Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Sep-18-23 04:15PM	Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update (GlobeNewswire) -5.15%
Sep-07-23 01:57PM	Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +28.95%
Sep-05-23 07:00AM	Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights (GlobeNewswire) +9.28%
Aug-30-23 10:34AM	Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide (GlobeNewswire)
Aug-21-23 03:24PM	Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite (PR Newswire)
Aug-05-23 03:30PM	10 Oversold Canadian Stocks To Buy (Insider Monkey)
02:53PM	10 Oversold Global Stocks To Buy (Insider Monkey)
Jul-31-23 07:00AM	Theratechnologies Completes 1-for-4 Reverse Stock Split (GlobeNewswire)
Jul-28-23 04:44PM	Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management (GlobeNewswire) +6.90%
Jul-21-23 07:00AM	Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn (GlobeNewswire) -7.88%
Jul-20-23 07:00AM	Theratechnologies Announces 1-for-4 Reverse Stock Split (GlobeNewswire) -5.67%
Jul-19-23 08:54AM	Theratechnologies (TSE:TH investor five-year losses grow to 88% as the stock sheds CA$16m this past week (Simply Wall St.) -6.57%
Jul-12-23 08:13AM	Theratechnologies: Fiscal Q2 Earnings Snapshot (AP Finance) -7.37%
07:30AM	Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jun-29-23 07:30AM	Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update (GlobeNewswire) -10.99%
Jun-22-23 07:30AM	Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management (GlobeNewswire)
Jun-12-23 07:30AM	Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial (GlobeNewswire)
Jun-02-23 12:15PM	Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide (GlobeNewswire) +9.90%
May-25-23 05:31PM	Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023 (GlobeNewswire) -5.26%
May-19-23 05:11PM	Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. (PR Newswire)
May-09-23 12:01PM	Theratechnologies Reports on its Annual Meeting of Shareholders (GlobeNewswire)
May-04-23 07:30AM	Theratechnologies Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison (GlobeNewswire) +8.58%
Apr-18-23 03:43PM	Theratechnologies Inc.'s (TSE:TH) Business And Shares Still Trailing The Industry (Simply Wall St.)
09:00AM	Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies (GlobeNewswire)

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montreal, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

THTX

Theratechnologies Inc

Upgrade your FINVIZ experience